General aspects and neuropathology of X-linked adrenoleukodystrophy

Brain Pathology

Volumn 20, Issue 4, 2010, Pages 817-830

  Ferrer, Isidro ^a   Aubourg, Patrick ^b   Pujol, Aurora ^a,c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Adrenoleukodystrophy; Adrenomyeloneuropathy; Autoimmunity; Gene therapy; Hematopoietic stem cell transplantation; Neurometabolic disease; Peroxisome; Very long chain fatty acids; X ALD

Indexed keywords

ABC TRANSPORTER; ABCD1 TRANSPORTER; CD1 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CORTICOSTEROID; CYTOKINE; GADOLINIUM; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; LIPID PEROXIDASE; LORENZO OIL; MEVINOLIN; MYELIN; TRIOLEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ADDISON DISEASE; ADRENOLEUKODYSTROPHY; BIOCHEMISTRY; BRAIN; CHILDHOOD ADRENOLEUKODYSTROPHY; CHILDHOOD DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; ENCEPHALITIS; EPIGENETICS; FAMILY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIPID PEROXIDATION; MITOCHONDRION; NERVE FIBER; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PEROXISOME; PROGNOSIS; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR; SYMPTOM; T LYMPHOCYTE ACTIVATION; WHITE MATTER; X CHROMOSOME LINKED DISORDER; GENETICS; PATHOLOGY;

ADRENOLEUKODYSTROPHY; BRAIN; GENETIC ASSOCIATION STUDIES; HUMANS;

EID: 77953216242     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2010.00390.x     Document Type: Conference Paper

References (159)

1. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet 14 : 1293 1303.
2. Aubourg P (1996) X-linked adrenoleukodystrophy. In : Handbook of Clinical Neurology, PJ Vinken, GW Bruyn, HW Moser (eds), pp. 447 483. Elsevier
3. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Lemaitre A, Boureau F, Mayer M, Kalifa G (1992) Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy. Neurology 42 : 85 91.
4. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I et al (1993) A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 329 : 745 752.
5. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C et al (1990) Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322 : 1860 1806.
6. Aubourg P, Diebler C (1982) Adrenoleukodystrophy - its diverse CT appearances and an evolutive or phenotypic variant: the leukodystrophy without adrenal insufficiency. Neuroradiology 24 : 33 42.
7. Aubourg P, Mandel JL (1996) X-linked adrenoleukodystrophy. Ann N Y Acad Sci 804 : 461 476.
8. Aubourg P, Sellier N, Chaussain JL, Kalifa G (1989) MRI detects cerebral involvement in neurologically asymptomatic patients with adrenoleukodystrophy. Neurology 39 : 1619 1621.
9. Berger J, Gartner J (2006) X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 1763 : 1721 1732.
10. Berger J, Molzer B, Fae I, Bernheimer H (1994) X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem Biophys Res Commun 205 : 1638 1643.
11. Berger J, Pujol A, Aubourg P, Forss-Petter S (2010) Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 20 : 845 856.
12. Bernheimer H, Budka H, Muller P (1983) Brain tissue immunoglobulins in adrenoleukodystrophy: a comparison with multiple sclerosis and systemic lupus erythematosus. Acta Neuropathol 59 : 95 102.
13. Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD et al (2001) Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 49 : 512 517.
14. Bizzozero OA, Zuniga G, Lees MB (1991) Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. J Neurochem 56 : 872 878.
15. Braiterman LT, Zheng S, Watkins PA, Geraghty MT, Johnson G, McGuinness MC et al (1998) Suppression of peroxisomal membrane protein defects by peroxisomal ATP binding cassette (ABC) proteins. Hum Mol Genet 7 : 239 247.
16. Brites P, Mooyer PA, El Mrabet L, Waterham HR, Wanders RJ (2009) Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 132 : 482 492.
17. Brooks BS, El Gammal T (1982) Case report. An additional case of adrenoleukodystrophy with both type I and type II CT features. J Comput Assist Tomogr 6 : 385 388.
18. Budka H, Sluga E, Heiss WD (1976) Spastic paraplegia associated with Addison's disease: adult variant of adreno-leukodystrophy. J Neurol 213 : 237 250.
19. Cartier N, Aubourg P (2010) Hematopoietic stem cell transplant and gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 20 : 857 862.
20. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 : 818 823.
21. Cartier N, Lopez J, Moullier P, Rocchiccioli F, Rolland MO, Jorge P et al (1995) Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci U S A 92 : 1674 1678.
22. Chaudhry V, Moser HW, Cornblath DR (1996) Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry 61 : 181 185.
23. Cohen SM, Green WR, de la Cruz ZC, Brown FR 3rd., Moser HW, Luckenbach MW et al (1983) Ocular histopathologic studies of neonatal and childhood adrenoleukodystrophy. Am J Ophthalmol 95 : 82 96.
24. Confort-Gouny S, Vion-Dury J, Chabrol B, Nicoli F, Cozzone PJ (1995) Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy. Neuroradiology 37 : 568 575.
25. Cox CS, Dubey P, Raymond GV, Mahmood A, Moser AB, Moser HW (2006) Cognitive evaluation of neurologically asymptomatic boys with X-linked adrenoleukodystrophy. Arch Neurol 63 : 69 73.
26. Deon M, Garcia MP, Sitta A, Barschak AG, Coelho DM, Schimit GO et al (2008) Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect. Metab Brain Dis 23 : 43 49.
27. Deon M, Sitta A, Barschak AG, Coelho DM, Pigatto M, Schmitt GO et al (2007) Induction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. Int J Dev Neurosci 25 : 441 444.
28. Deon M, Sitta A, Barschak AG, Coelho DM, Terroso T, Schmitt GO et al (2008) Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J Neurol Sci 266 : 79 83.
29. Di Biase A, Merendino N, Avellino C, Cappa M, Salvati S (2001) Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy. J Neurol Sci 182 : 161 165.
30. Di Chiro G, Eiben RM, Manz HJ, Jacobs IB, Schellinger D (1980) A new CT pattern in adrenoleukodystrophy. Radiology 137 : 687 692.
31. Dohle CI, Bannykh SI, Hisama FM, Baehring JM (2009) Leukoencephalopathy in adults: is it adrenoleukodystrophy? A case report and molecular analysis. J Neurol Sci 285 : 235 237.
32. Dubey P, Fatemi A, Barker PB, Degaonkar M, Troeger M, Zackowski K et al (2005) Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy. Neurology 64 : 304 310.
33. Dubey P, Fatemi A, Huang H, Nagae-Poetscher L, Wakana S, Barker PB et al (2005) Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. Ann Neurol 58 : 758 766.
34. Dubois PJ, Freemark M, Lewis D, Drayer BP, Heinz ER, Osborne D (1981) Case report. Atypical findings in adrenoleukodystrophy. J Comput Assist Tomogr 5 : 888 891.
35. Dubois-Dalcq M, Feigenbaum V, Aubourg P (1999) The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci 22 : 4 12.
36. Duda EE, Huttenlocher PR (1976) Computed tomography in adrenoleukodystrophy. Correlation of radiological and histological findings. Radiology 120 : 349 350.
37. Dumser M, Bauer J, Lassmann H, Berger J, Forss-Petter S (2007) Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency. Acta Neuropathol 114 : 573 586.
38. Eiben RM, Di Chiro G (1977) Computer assisted tomography in adrenoleukodystrophy. J Comput Assist Tomogr 1 : 308 314.
39. Eichler FS, Barker PB, Cox C, Edwin D, Ulug AM, Moser HW, Raymond GV (2002) Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 58 : 901 907.
40. Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, Moser AB et al (2008) Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 63 : 729 742.
41. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V et al (2005) Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 14 : 3565 3577.
42. Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab MH et al (1997) Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res 50 : 829 843.
43. Fouquet F, Zhou JM, Ralston E, Murray K, Troalen F, Magal E et al (1997) Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Neurobiol Dis 3 : 271 285.
44. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M et al (2008) Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 17 : 1762 1773.
45. Fourcade S, Ruiz M, Camps C, Schluter A, Houten SM, Mooyer PA et al (2009) A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 296 : E211 E221.
46. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A et al (2010) Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet Epub ahead of print PMID:20179078.
47. Furushima W, Inagaki M, Gunji A, Inoue Y, Kaga M, Mizutani S (2009) Early signs of visual perception and evoked potentials in radiologically asymptomatic boys with X-linked adrenoleukodystrophy. J Child Neurol 24 : 927 935.
48. Garashi M, Belchis D, Suzuki K (1976) Brain gangliosides in adrenoleukodystrophy. J Neurochem 27 : 327 328.
49. Gilg AG, Singh AK, Singh I (2000) Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. J Neuropathol Exp Neurol 59 : 1063 1069.
50. Glasgow BJ, Brown HH, Hannah JB, Foos RY (1987) Ocular pathologic findings in neonatal adrenoleukodystrophy. Ophthalmology 94 : 1054 1060.
51. Grainger BT, Papchenko TL, Danesh-Meyer HV (2010) Optic nerve atrophy in adrenoleukodystrophy detectable by optic coherence tomography. J Clin Neurosci 17 : 122 124.
52. Greenberg HS, Halverson D, Lane B (1977) CT scanning and diagnosis of adrenoleukodystrophy. Neurology 27 : 884 886.
53. Griffin DE, Moser HW, Mendoza Q, Moench TR, O'Toole S, Moser AB (1985) Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 18 : 660 664.
54. Griffin JW, Goren E, Schaumburg H, Engel WK, Loriaux L (1977) Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects. Neurology 27 : 1107 1113. (Pubitemid 8260722)
55. Heinzer AK, McGuinness MC, Lu JF, Stine OC, Wei H, Van der Vlies M et al (2003) Mouse models and genetic modifiers in X-linked adrenoleukodystrophy. Adv Exp Med Biol 544 : 75 93.
56. Heinzer AK, Watkins PA, Lu JF, Kemp S, Moser AB, Li YY et al (2003) A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Hum Mol Genet 12 : 1145 1154.
57. Hettema EH, van Roermund CW, Distel B, van den Berg M, Vilela C, Rodrigues-Pousada C et al (1996) The ABC transporter proteins Pat1 and Pat2 are required for import of long-chain fatty acids into peroxisomes of Saccharomyces cerevisiae. EMBO J 15 : 3813 3822.
58. Hoftberger R, Kunze M, Weinhofer I, Aboul-Enein F, Voigtlander T, Oezen I et al (2007) Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol Dis 28 : 165 174.
59. Holzinger A, Kammerer S, Berger J, Roscher AA (1997) cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 239 : 261 264.
60. Holzinger A, Mayerhofer P, Berger J, Lichtner P, Kammerer S, Roscher AA (1999) Full length cDNA cloning, promoter sequence, and genomic organization of the human adrenoleukodystrophy related (ALDR) gene functionally redundant to the gene responsible for X-linked adrenoleukodystrophy. Biochem Biophys Res Commun 258 : 436 442.
61. Hubbard WC, Moser AB, Liu AC, Jones RO, Steinberg SJ, Lorey F et al (2009) Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 97 : 212 220.
62. Hudspeth MP, Raymond GV (2007) Immunopathogenesis of adrenoleukodystrophy: current understanding. J Neuroimmunol 182 : 5 12.
63. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K (1976) Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 26 : 851 860.
64. Ito M, Blumberg BM, Mock DJ, Goodman AD, Moser AB, Moser HW et al (2001) Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 60 : 1004 1019.
65. Kaga M, Furushima W, Inagaki M, Nakamura M (2009) Early neuropsychological signs of childhood adrenoleukodystrophy (ALD). Brain Dev 31 : 558 561.
66. Kashiwayama Y, Seki M, Yasui A, Murasaki Y, Morita M, Yamashita Y et al (2009) 70-kDa peroxisomal membrane protein related protein (P70R/ABCD4) localizes to endoplasmic reticulum not peroxisomes, and NH2-terminal hydrophobic property determines the subcellular localization of ABC subfamily D proteins. Exp Cell Res 315 : 190 205.
67. Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, Raymond GV et al (2001) ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 18 : 499 515.
68. Kemp S, Wanders RJ (2007) X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol Genet Metab 90 : 268 276.
69. Kemp S, Wanders RJ (2010) Biochemical aspects of X-adrenoleukodystrophy. Brain Pathol 20 : 831 837.
70. Khan M, Singh J, Singh I (2008) Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem 106 : 1766 1779.
71. Kim WS, Weickert CS, Garner B (2008) Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 104 : 1145 1166.
72. Kobayashi T, Shinnoh N, Kondo A, Yamada T (1997) Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun 232 : 631 636.
73. Kruse B, Barker PB, van Zijl PC, Duyn JH, Moonen CT, Moser HW (1994) Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 36 : 595 608.
74. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I (1988) Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A 85 : 7647 7651.
75. Li JY, Hsu CC, Tsai CR (2010) Spinocerebellar variant of adrenoleukodystrophy with a novel ABCD1 gene mutation. J Neurol Sci 290 : 163 165.
76. Linnebank M, Kemp S, Wanders RJ, Kleijer WJ, van der Sterre ML, Gartner J et al (2006) Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. Neurology 66 : 442 443.
77. Liu J, Sabeva NS, Bhatnagar S, Li XA, Pujol A, Graf GA (2010) ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat. J Lipid Res 51 : 162 168.
78. Liu LX, Janvier K, Berteaux-Lecellier V, Cartier N, Benarous R, Aubourg P (1999) Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J Biol Chem 274 : 32738 32743.
79. Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L et al (1994) Adrenoleukodystrophy: a scoring method for brain MR observations. Am J Neuroradiol 15 : 1761 1766.
80. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, Smith KD (1997) A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A 94 : 9366 9371.
81. Maier EM, Mayerhofer PU, Asheuer M, Kohler W, Rothe M, Muntau AC et al (2008) X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun 377 : 176 180.
82. Marler JR, O'Neill BP, Forbes GS, Moser HW (1983) Adrenoleukodystrophy (ALD): clinical and CT features of a childhood variant. Neurology 33 : 1203 1205.
83. Mastroeni R, Bensadoun JC, Charvin D, Aebischer P, Pujol A, Raoul C (2009) Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol 66 : 117 122.
84. McDonald MI, Corey GR, Gallis HA, Durack DT (1984) Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine 63 : 291 302.
85. McGuinness MC, Lu JF, Zhang HP, Dong GX, Heinzer AK, Watkins PA et al (2003) Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 23 : 744 753.
86. McGuinness MC, Powers JM, Bias WB, Schmeckpeper BJ, Segal AH, Gowda VC et al (1997) Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol 75 : 174 182.
87. McGuinness MC, Zhang HP, Smith KD (2001) Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol Genet Metab 74 : 256 263.
88. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA (1981) Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci U S A 78 : 5066 5070.
89. Mirowitz S, Sartor K, Gado M, Torack R (1989) Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathologic findings. Radiology 172 : 535 539.
90. Mishra S, Modi M, Das CP, Prabhakar S (2006) Adrenoleukodystrophy manifesting as spinocerebellar degeneration. Neurol India 54 : 195 196.
91. Moody DB (2006) The surprising diversity of lipid antigens for CD1-restricted T cells. Adv Immunol 89 : 87 139.
92. Moody DB, Besra GS, Wilson IA, Porcelli SA (1999) The molecular basis of CD1-mediated presentation of lipid antigens. Immunol Rev 172 : 285 296.
93. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-Mir C, O'Connor PB et al (2004) T cell activation by lipopeptide antigens. Science 303 : 527 531.
94. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S, Moser HW (1999) Plasma very long chain fatty acids in 3000 peroxisome disease patients and 29 000 controls. Ann Neurol 45 : 100 110.
95. Moser AB, Moser HW (1999) The prenatal diagnosis of X-linked adrenoleukodystrophy. Prenat Diagn 19 : 46 48.
96. Moser H, Smith KD, Watkins PA, Powers J, Moser AB (2001) X-linked adrenoleukodystrophy. In : The Metabolic and Molecular Bases of Inherited Disease, C Scriver (ed.) pp. 3257 3301. McGraw-Hill
97. Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120 : 1485 1508.
98. Moser HW (2006) Therapy of X-linked adrenoleukodystrophy. NeuroRx 3 : 246 253.
99. Moser HW, Mahmood A, Raymond GV (2007) X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3 : 140 151.
100. Moser HW, Moser AE, Trojak JE, Supplee SW (1983) Identification of female carriers of adrenoleukodystrophy. J Pediatr 103 : 54 59.
101. Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J et al (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 62 : 1073 1080.
102. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H et al (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361 : 726 730.
103. Mosser J, Lutz Y, Stoeckel ME, Sarde CO, Kretz C, Douar AM et al (1994) The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 3 : 265 271. (Pubitemid 24060941)
104. Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, Berger J (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum Mol Genet 8 : 907 913.
105. Oezen I, Rossmanith W, Forss-Petter S, Kemp S, Voigtlander T, Moser-Thier K et al (2005) Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency. Hum Mol Genet 14 : 1127 1137.
106. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, Singh I (2003) Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 14 : 425 439.
107. Powers J (2008) Peroxisomal disorders. In : Greenfield's Neuropathology, S Love, D Louis, D Ellison (eds), pp. 643 673. London
108. Powers JM (2005) Adreno-leukodystrophy: a personal historical note. Acta Neuropathol 109 : 124 127.
109. Powers JM, DeCiero DP, Cox C, Richfield EK, Ito M, Moser AB, Moser HW (2001) The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 60 : 493 501.
110. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW (2000) Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 59 : 89 102.
111. Powers JM, Liu Y, Moser AB, Moser HW (1992) The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 51 : 630 643.
112. Powers JM, Moser HW, Moser AB, Ma CK, Elias SB, Norum RA (1987) Pathologic findings in adrenoleukodystrophy heterozygotes. Arch Pathol Lab Med 111 : 151 153.
113. Powers JM, Moser HW, Moser AB, Schaumburg HH (1982) Fetal adrenoleukodystrophy: the significance of pathologic lesions in adrenal gland and testis. Hum Pathol 13 : 1013 1019.
114. Powers JM, Pei Z, Heinzer AK, Deering R, Moser AB, Moser HW et al (2005) Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 64 : 1067 1079.
115. Powers JM, Schaumberg HH (1974) Adreno-leukodystrophy. Similar ultrastructural changes in adrenal cortical and Schwann cells. Arch Neurol 30 : 406 408.
116. Powers JM, Schaumburg HH (1981) The testis in adreno-leukodystrophy. Am J Pathol 102 : 90 98.
117. Powers JM, Schaumburg HH, Johnson AB, Raine CS (1980) A correlative study of the adrenal cortex in adreno-leukodystrophy - evidence for a fatal intoxication with very long chain saturated fatty acids. Invest Cell Pathol 3 : 353 376.
118. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N et al (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 13 : 2997 3006.
119. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 11 : 499 505.
120. Pujol A, Singh I (2010) Pathomechanisms of X-adrenoleukodystrophy: an hypothesis. Brain Pathol 20 : 838 844.
121. Ratai E, Kok T, Wiggins C, Wiggins G, Grant E, Gagoski B et al (2008) Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch Neurol 65 : 1488 1494.
122. Raymond GV, Jones RO, Moser AB (2007) Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther 11 : 381 384.
123. Roerig P, Mayerhofer P, Holzinger A, Gartner J (2001) Characterization and functional analysis of the nucleotide binding fold in human peroxisomal ATP binding cassette transporters. FEBS Lett 492 : 66 72.
124. Romero C, Dietemann JL, Kurtz D, Bataillard M, Christmann D (1990) Adrenoleukodystrophy. Value of contrast-enhanced MR imaging. J Neuroradiol 17 : 267 276.
125. Savary S, Troffer-Charlier N, Gyapay G, Mattei MG, Chimini G (1997) Chromosomal localization of the adrenoleukodystrophy-related gene in man and mice. Eur J Hum Genet 5 : 99 101.
126. Schaumburg HH, Powers JM, Raine CS, Johnson AB, Kolodny EH, Kishmoto Y et al (1976) The myeloneuropathy variant of adrenoleukodystrophy. J Neuropathol Exp Neurol 35 : 312.
127. Schaumburg HH, Powers JM, Raine CS, Spencer PS, Griffin JW, Prineas JW, Boehme DM (1977) Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic, and biochemical aspects. Neurology 27 : 1114 1119.
128. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP Jr. (1975) Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol 32 : 577 591.
129. Schmidt S, Haase CG, Bezman L, Moser H, Schmidt M, Kohler W et al (2001) Serum autoantibody responses to myelin oligodendrocyte glycoprotein and myelin basic protein in X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol 119 : 88 94.
130. Semmler A, Bao X, Cao G, Kohler W, Weller M, Aubourg P, Linnebank M (2009) Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol 256 : 1277 1280.
131. Semmler A, Kohler W, Jung HH, Weller M, Linnebank M (2008) Therapy of X-linked adrenoleukodystrophy. Expert Rev Neurother 8 : 1367 1379.
132. Shinnoh N, Yamada T, Yoshimura T, Furuya H, Yoshida Y, Suzuki Y et al (1995) Adrenoleukodystrophy: the restoration of peroxisomal beta-oxidation by transfection of normal cDNA. Biochem Biophys Res Commun 210 : 830 836.
133. Singh I, Khan M, Key L, Pai S (1998) Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 339 : 702 703.
134. Singh I, Moser AE, Moser HW, Kishimoto Y (1984) Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res 18 : 286 290.
135. Singh J, Khan M, Singh I (2009) Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res 50 : 135 147.
136. Smith BT, Sengupta TK, Singh I (2000) Intraperoxisomal localization of very-long-chain fatty acyl-CoA synthetase: implication in X- adrenoleukodystrophy. Exp Cell Res 254 : 309 320.
137. Sutovsky S, Petrovic R, Chandoga J, Turcani P (2007) Adult onset cerebral form of X-linked adrenoleukodystrophy with dementia of frontal lobe type with new L160P mutation in ABCD1 gene. J Neurol Sci 263 : 149 153.
138. Theda C, Moser AB, Powers JM, Moser HW (1992) Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 110 : 195 204.
139. Traboulsi EI, Maumenee IH (1987) Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy. Ophthalmology 94 : 47 52.
140. Troffer-Charlier N, Doerflinger N, Metzger E, Fouquet F, Mandel JL, Aubourg P (1998) Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines. Eur J Cell Biol 75 : 254 264.
141. Tzika AA, Ball WS Jr., Vigneron DB, Dunn RS, Nelson SJ, Kirks DR (1993) Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. Radiology 189 : 467 480.
142. Uchiyama A, Aoyama T, Kamijo K, Uchida Y, Kondo N, Orii T, Hashimoto T (1996) Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase. J Biol Chem 271 : 30360 30365.
143. Uchiyama M, Hata Y, Tada S (1991) MR imaging of adrenoleukodystrophy. Neuroradiology 33 : 25 29.
144. Uto T, Contreras MA, Gilg AG, Singh I (2008) Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci 30 : 410 418.
145. Valianpour F, Selhorst JJ, van Lint LE, van Gennip AH, Wanders RJ, Kemp S (2003) Analysis of very long-chain fatty acids using electrospray ionization mass spectrometry. Mol Genet Metab 79 : 189 196.
146. van der Knaap MS, Valk J (1989) MR of adrenoleukodystrophy: histopathologic correlations. Am J Neuroradiol 10 : S12 S14.
147. van Geel BM, Assies J, Wanders RJ, Barth PG (1997) X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry 63 : 4 14.
148. van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV (2001) Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 49 : 186 194.
149. van Geel BM, Koelman JH, Barth PG, Ongerboer de Visser BW (1996) Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology 46 : 112 118.
150. Van Rhijn I, Zajonc DM, Wilson IA, Moody DB (2005) T-cell activation by lipopeptide antigens. Curr Opin Immunol 17 : 222 229.
151. van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W et al (2008) The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J 22 : 4201 4208.
152. Vargas CR, Wajner M, Sirtori LR, Goulart L, Chiochetta M, Coelho D et al (2004) Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 1688 : 26 32.
153. Wanders RJ, van Roermund CW, van Wijland MJ, Schutgens RB, Schram AW, Tager JM et al (1988) X-linked adrenoleukodystrophy: identification of the primary defect at the level of a deficient peroxisomal very long chain fatty acyl-CoA synthetase using a newly developed method for the isolation of peroxisomes from skin fibroblasts. J Inherit Metab Dis 11 (Suppl. 2 173 177.
154. Wanders RJ, van Roermund CW, van Wijland MJ, Schutgens RB, van den Bosch H, Schram AW, Tager JM (1988) Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Commun 153 : 618 624.
155. Wanders RJ, Visser WF, van Roermund CW, Kemp S, Waterham HR (2007) The peroxisomal ABC transporter family. Pflugers Arch 453 : 719 734.
156. Wilichowski E, Ohlenbusch A, Korenke GC, Hunneman DH, Hanefeld F (1998) Identical mitochondrial DNA in monozygotic twins with discordant adrenoleukodystrophy phenotype. Ann Neurol 43 : 835 836.
157. Yamada T, Shinnoh N, Kondo A, Uchiyama A, Shimozawa N, Kira J, Kobayashi T (2000) Very-long-chain fatty acid metabolism in adrenoleukodystrophy protein-deficient mice. Cell Biochem Biophys 3 : 239 246.
158. Young DC, Moody DB (2006) T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology 16 : 103R 112R.
159. Young RS, Ramer JC, Towfighi J, Weidner W, Lehman R, Moser HW (1982) Adrenoleukodystrophy: unusual computed tomographic appearance. Arch Neurol 39 : 782 783.